News >

Pixantrone Falls Short in Phase III B-Cell NHL Trial

Jason M. Broderick @jasoncology
Published: Monday, Jul 09, 2018

Blood cells
Combining pixantrone (Pixuvri) with rituximab (Rituxan) failed to improve progression-free survival (PFS) compared with gemcitabine plus rituximab in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) enrolled in the phase III PIX306 trial, according to CTI BioPharma, the manufacturer of pixantrone.

CTI did not conduct an additional trial at the time. The company instead appealed the CRL and provided additional analysis of the EXTEND findings with its resubmission of its NDA to the FDA in October 2011. A second ODAC meeting was then set for February 9, 2012, to review CTI’s resubmitted NDA. However, on January 30, 2012, CTI announced that it had withdrawn its NDA after the FDA did not meet its request to reschedule the ODAC meeting to late March 2012.  

References

  1. Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review. Published June 24, 2009. Accessed July 9, 2018. https://bit.ly/2u7Ab6V.
  2. 18-month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkin's Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherapy. Published September 16, 2009. Accessed July 9, 2018. https://bit.ly/2m2TJFd
 

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x